Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit
- 30 April 2012
- journal article
- Published by Elsevier BV in Experimental Eye Research
- Vol. 97 (1), 154-159
- https://doi.org/10.1016/j.exer.2011.09.002
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedemaBritish Journal of Ophthalmology, 2009
- The Pharmacology Study of a New Recombinant Human VEGF Receptor-Fc Fusion Protein on Experimental Choroidal NeovascularizationPharmaceutical Research, 2008
- Clinical update: new treatments for age-related macular degenerationThe Lancet, 2007
- Structure of a VEGF–VEGF receptor complex determined by electron microscopyNature Structural & Molecular Biology, 2007
- Crystal Structures of Novel Vascular Endothelial Growth Factors (VEGF) from Snake VenomsPublished by Elsevier BV ,2005
- Regression of established tumors and metastases by potent vascular endothelial growth factor blockadeProceedings of the National Academy of Sciences of the United States of America, 2003
- VEGF‐TRAPR1R2 suppresses choroidal neovascularization and VEGF‐induced breakdown of the blood–retinal barrierJournal of Cellular Physiology, 2003
- VEGF-Trap: A VEGF blocker with potent antitumor effectsProceedings of the National Academy of Sciences of the United States of America, 2002
- Vascular endothelial growth factor is essential for corpus luteum angiogenesisNature Medicine, 1998